Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA
Author:
Affiliation:
1. Mount Sinai School of Medicine, New York, NY 10029, USA
2. Policy Analysis Inc., Chestnut Hill, MA 02467, USA
3. Bristol Myers Squibb, Princeton, NJ 08540, USA
Abstract
Funder
Bristol-Myers Squibb
Publisher
Future Medicine Ltd
Subject
Cancer Research,Oncology,General Medicine
Link
https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-1003
Reference27 articles.
1. American Cancer Society. Cancer facts and figures 2019. (2020). http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
2. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for multiple myeloma (2020). V.3.2021. https://www.nccn.org/professionals/physician_gls/default.aspx
3. Burden of disease progression in patients with multiple myeloma in the US
4. Multiple myeloma: patient outcomes in real‐world practice
5. The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States;Journal of Managed Care & Specialty Pharmacy;2024-09-09
2. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma;Current Medical Research and Opinion;2024-09-03
3. From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population;Oncology and Therapy;2024-08-04
4. Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08
5. Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data;Current Medical Research and Opinion;2024-04-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3